An additional important use for measuring BACE2 cleavage–specific plasma sVEGFR3 is the development of a new generation of drugs specifically targeting BACE1, but not BACE2, for safer treatment of AD and, conversely, the development of BACE2-selective inhibitors (avoiding BACE1 inhibition) for potential treatment and measuring treatment responses in melanoma, glioblastoma, and diabetes, where inhibition of BACE2 is considered as a therapeutic approach (8, 12). The gene discussed is BACE2; the disease is diabetes mellitus.